临床外科杂志 ›› 2024, Vol. 32 ›› Issue (11): 1175-1178.doi: 10.3969/j.issn.1005-6483.20231332

• 论著 • 上一篇    下一篇

血清骨桥蛋白,血管生成素样蛋白8水平与原发性肝癌病人介入治疗后肝纤维化的相关性

  

  1. 056000  河北省邯郸市第一医院介入血管外科
  • 收稿日期:2023-10-13 接受日期:2023-10-13 出版日期:2024-11-20 发布日期:2024-11-20
  • 通讯作者: 夏化文,Email:x71sry@163.com
  • 基金资助:
    2022年度河北省中医药类科研计划课题(2022664)

Correlation between serum OPN, ANGPTL8 levels in patients with primary liver cancer and liver fibrosis after interventional therapy

  1. Department of Interventional Vascular Surgery,the First Hospital of Handan City, Hebei 056000, China
  • Received:2023-10-13 Accepted:2023-10-13 Online:2024-11-20 Published:2024-11-20

摘要: 目的  探讨原发性肝癌(PHC)病人血清骨桥蛋白(OPN)、血管生成素样蛋白8(ANGPTL8)水平与经导管动脉化疗栓塞术(TACE)后肝纤维化(HF)的相关性。方法  2021年3月~2023年6月期间收治的PHC病人166例,根据介入治疗后是否发生HF分为两组,其中发生HF的病人92例,为观察组,未发生HF的病人74例,为对照组;酶联免疫吸附法(ELISA)测定血清OPN、ANGPTL8水平并分析OPN、ANGPTL8水平对HF的预测价值。采用Pearson相关性分析 OPN、ANGPTL8水平与生化指标的相关性;采用多因素Logistics回归分析影响 HF发生的因素;采用ROC曲线分析 OPN、ANGPTL8对 HF的预测价值。结果  观察组血清OPN [(74.56±11.56)ng/ml]、ANGPTL[(42.78±5.23)ng/ml]、ALT[(62.24±9.56)U/L]、AST[(42.88±8.23)U/L]、HA[(252.98±52.44)ng/L]、LN[(152.64±26.45)ng/L]、PCⅢ[(16.54±3.46)ng/L]、Ⅳ-C[(152.78±21.23)ng/L]水平明显高于对照组[(57.89±9.68)ng/ml、(35.46±4.78)ng/ml、(49.46±7.46)U/L、(31.48±7.26)U/L、(192.56±23.88)ng/L、(124.48±11.23)ng/L、(11.26±2.23)ng/L、(126.45±18.56)ng/L],两组比较,差异有统计学意义(P<0.05)。血清OPN、ANGPTL8及二者联合预测HF发生的AUC分别为0.914、0.920、0.978,OPN联合ANGPTL8预测HF发生的AUC高于二者分别单独预测(P<0.05)。结论  PHC病人血清OPN、ANGPTL8水平与HF的发生密切相关,二者是HF发生的影响因素,可作为预测HF发生的指标。

关键词: 原发性肝癌, 介入治疗, 肝纤维化, 骨桥蛋白, 血管生成素样蛋白8

Abstract: Objective  To investigate the correlation between serum osteoblastin (OPN) and angiopoietin-like protein 8 (ANGPTL8) levels and hepatic fibrosis (HF) after interventional therapy-transcatheter arterial chemoembolisation (TACE) in patients with primary hepatocellular carcinoma (PHC). Methods 166 patients with PHC admitted between March 2021 and June 2023 were selected and divided into 92 cases with HF (observation group) and 74 cases without HF (control group) according to whether or not HF occurred after interventional therapy; enzyme-linked immunosorbent assay (ELISA) was used to determine the serum OPN and ANGPTL8 levels and to analyse the predictive value of the OPN and ANGPTL8 levels on HF.Pearson correlation was used to analyze the correlation between OPN and ANGPTL8 levels and biochemical indexes.The factors influencing the occurrence of HF were analyzed by multi-factor Logistics- regression. ROC curve was used to analyze the predictive value of OPN and ANGPTL8 for HF. Results  Serum OPN [(74.56±11.56) ng/ml], ANGPTL [(42.78±5.23) ng/ml], ALT [(62.24±9.56) U/L], AST [(42.88±8.23) U/L], HA [(252.98±52.44) ng/L], LN [(152.64±26.45) ng/L], PCⅢ[(16.54±3.46)ng/L] and Ⅳ-C[(152.78±21.23)ng/L] in observation group were significantly higher than the control group[(57.89±9.68)ng/ml,(35.46±4.78)ng/ml,(49.46±7.46)U/L,(31.48±7.26)U/L,(192.56±23.88)ng/L,(124.48±11.23)ng/L,(11.26±2.23)ng/L and (126.45±18.56)ng/L].The differences between the two groups were statistically significant (P<0.05). The AUC of serum OPN, ANGPTL8 and the combination of the two in predicting the occurrence of HF were 0.914, 0.920 and 0.978, respectively, and the AUC of OPN combined with ANGPTL8 in predicting the occurrence of HF was higher than the AUC of the two separately (P<0.05). Conclusion  The levels of serum OPN and ANGPTL8 of patients with PHC are closely associated with the occurrence of HF, and the two are HF occurrence influencing factors and can be used as indicators to predict the occurrence of HF.

Key words: primary hepatic carcinoma, interventional therapy, liver fibrosis, osteopontin, angiopoietin like protein 8

[1] 汪明泉 王会哲 卢双动 王谦 蔡增强. 血清尿酸水平对原发性肝癌病人肝切除术后肌少症发生的预测价值研究[J]. 临床外科杂志, 2024, 32(9): 937-941.
[2] 杨帆 段建峰 丁建龙 赵喜荣 段昌虎 吴林 赵李飞. 血清8-羟基脱氧鸟苷和连接蛋白4对原发性肝癌经导管肝动脉栓塞术后疗效的评估价值[J]. 临床外科杂志, 2024, 32(8): 840-843.
[3] 殷强 胡勇军 汪磊 晏华军 沈雄山. 三维重建技术在肝癌腹腔镜肝切除术中的应用体会[J]. 临床外科杂志, 2024, 32(5): 499-501.
[4] 李轶 尚立. 肝硬化病人血清lncRNA TUG1表达水平与肝功能、肝纤维化程度的相关性研究[J]. 临床外科杂志, 2024, 32(3): 281-284.
[5] 陈磊 唐彤 张代忠 柳凤玲 杨中秋 严欢. 腹腔镜下射频消融和经皮射频消融治疗原发性肝癌的效果观察[J]. 临床外科杂志, 2024, 32(11): 1179-1183.
[6] 魏萌萌 吕志坤 李国珍 胡雪艳 许倩倩 郭静 耿彪. 血清血管生成素样蛋白8、血管细胞黏附分子-1水平联合检测对颅内动脉瘤栓塞术后脑血管痉挛的预测价值[J]. 临床外科杂志, 2023, 31(12): 1133-1136.
[7] 文静 贾哲 赫嵘 张宏伟 张珂. 原发性肝癌合并肝硬化门静脉高压症腹腔镜断流术同期联合肝切除或射频消融手术腹腔感染危险因素分析[J]. 临床外科杂志, 2023, 31(11): 1053-1056.
[8] 毕华强 夏锋. 免疫时代肝癌外科治疗策略的转变与挑战[J]. 临床外科杂志, 2023, 31(10): 904-906.
[9] 张佳 马魏杰 袁玉峰. 原发性肝癌免疫节点抑制剂疗法的研究进展[J]. 临床外科杂志, 2023, 31(10): 916-919.
[10] 蔺金军 刘俊华 慕立峰 黄占有 魏军龙 李永梅. 胃癌手术、介入化疗后存活19年一例[J]. 临床外科杂志, 2022, 30(9): 828-829.
[11] 张济, 李光泽, 俞慎林等. 血清高迁移率族蛋白B1、髓系细胞触发受体1对下肢动脉硬化闭塞症病人介入治疗后再狭窄的预测价值[J]. 临床外科杂志, 2021, 29(6): 573-576.
[12] 窦宁, 谭晶晶, 李子林. 动脉导管未闭介入治疗日间手术的短期临床结果[J]. 临床外科杂志, 2021, 29(2): 178-180.
[13] 方小三 王小明 韩婷 蒋彬 王冠男 奚士航. 原发性肝癌病人腹腔镜肝叶切除术后并发胆漏的风险预测模型构建[J]. 临床外科杂志, 2021, 29(11): 1030-1033.
[14] 王观宇. 肝癌转化治疗的策略和现状[J]. 临床外科杂志, 2021, 29(11): 1012-1014.
[15] 林天生 陈忠. 胰十二指肠切除术后迟发出血的影响因素及处理策略分析[J]. 临床外科杂志, 2020, 28(9): 867-870.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 宫念樵. 器官捐献供肾质量评估[J]. 临床外科杂志, 2016, 24(10): 729 .
[2] 邱江. 心脏死亡捐献供肾移植免疫抑制方案的选择[J]. 临床外科杂志, 2016, 24(10): 735 .
[3] 昌盛. 中国心脏死亡捐献供肾器官的维护[J]. 临床外科杂志, 2016, 24(10): 744 .
[4] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[5] 阿布力克木·毛拉尤甫;郑秉礼. 胰腺实性假乳头状瘤45例手术治疗分析[J]. 临床外科杂志, 2016, 24(10): 764 .
[6] 戴强;徐康;周治军;等. 湖北天门地区泌尿系结石成分及特征分析[J]. 临床外科杂志, 2016, 24(10): 789 .
[7] 胡光俊;宋晓阳;陶军. 右美托咪定添加到罗哌卡因中对腰丛坐骨神经阻滞及镇静的影响[J]. 临床外科杂志, 2016, 24(10): 796 .
[8] 曹志新. 基于膜解剖的胃癌D2手术[J]. 临床外科杂志, 2016, 24(11): 812 .
[9] 石汉平. 胃癌围手术期营养治疗[J]. 临床外科杂志, 2016, 24(11): 821 .
[10] 王维君;那光玮;何科基;等. 根治性淋巴结清扫联合脾切除在残胃癌手术中的临床意义探究[J]. 临床外科杂志, 2016, 24(11): 835 .